Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
Axsome Therapeutics, Inc. AXSM incurred an adjusted loss of $1.34 per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.38. The company had incurred a loss...
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript
AXSM earnings call for the period ending September 30, 2024.
10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday
Earnings have largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market.
Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed...